Hann departs as Biomet details initial findings from stock option probe
This article was originally published in Clinica
Executive Summary
Preliminary investigations by Biomet into its stock option grants over the past 11 years have led to the departure of Daniel Hann, the company's former general counsel who served as interim CEO until February 26, when he became executive vice-president of administration.